Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Stratified Treatment for Pediatric Ewing Sarcoma
NCT06451302Active, not recruiting
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide, doxorubicin, vincristine, ifosfamide and etoposide in Ewing sarcoma. Primary endpoint: Objective Response Rate at 5 years. Started Apr 2024; status: active, not recruiting.
02
Drugs
cyclophosphamidedoxorubicinvincristineifosfamideetoposide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT06451302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451302.